A novel combinatorial treatment option for metastatic uveal melanoma

Area of Science:

• Ophthalmology
• Oncology
• Molecular Biology

Background:

• Uveal melanoma (UM) is the most common intraocular tumor in adults.
• Metastatic UM (mUM) has limited treatment options with modest efficacy.
• Current systemic therapies for mUM include alkylating agents like dacarbazine (DTIC), while doxorubicin (DOX) is not utilized.

Purpose of the Study:

• To evaluate the efficacy of doxorubicin (DOX) in treating UM cell mortality.
• To explore the potential of combining CREB knockdown with chemotherapy for mUM treatment.
• To investigate the synergistic effects of CREB knockdown and chemotherapy under normoxic and hypoxic conditions.

Main Methods:

• UM cells were infected with retroviruses (RCR) expressing shRNA targeting CREB.
• Cells were co-treated with either DTIC or DOX under normoxia and hypoxia.
• Cell survival and Caspase 3 activation were measured to assess treatment efficacy.

Main Results:

• CREB knockdown significantly increased UM cell sensitivity to both DOX and DTIC.
• The enhanced sensitivity was more pronounced under hypoxic conditions.
• Caspase 3 activation indicated increased apoptosis in treated cells.

Conclusions:

• CREB knockdown potentiates the efficacy of standard chemotherapies (DOX, DTIC) in UM cells.
• This combination therapy shows promise, particularly under hypoxia.
• Combining retroviral CREB knockdown with chemotherapy offers a potential novel treatment strategy for mUM with potentially reduced drug side effects.